Compare Stocks

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUC EOM Pharmaceuticals	$0.20	$0.18	$0.10 ▼ $0.40	N/A	0.23	2,131 shs	296 shs
IMUCD ImmunoCellular Therapeutics	$0.20	$0.19	$0.16 ▼ $0.51	$834K	1.63	6,605 shs	296 shs
NSPX Inspyr Therapeutics		$0.00	$0.00 ▼ $0.07	$1.47M	-17.33	13.19 million shs	29.64 million shs
NXEN Nexien BioPharma	$0.02	$0.02	$0.01 ▼ $0.10	$1.68M	1.47	9,727 shs	18,128 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUC EOM Pharmaceuticals	0.00%	+0.51%	+8.18%	-17.08%	-10.84%
IMUCD ImmunoCellular Therapeutics	0.00%	+11.17%	+8.18%	-5.24%	-36.18%
NSPX Inspyr Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NXEN Nexien BioPharma	+16.39%	+68.90%	+65.87%	+81.05%	-38.44%

The only AI company to buy (Ad)

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMUCD ImmunoCellular Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NXEN Nexien BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A
IMUCD ImmunoCellular Therapeutics	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A
NXEN Nexien BioPharma	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
IMUCD ImmunoCellular Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
NXEN Nexien BioPharma	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMUC EOM Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IMUCD ImmunoCellular Therapeutics	-$14.31M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	-$6.30M	N/A	0.00	N/A	N/A	N/A	N/A	-1,354.49%	N/A
NXEN Nexien BioPharma	-$360K	-$0.01	N/A	∞	N/A	N/A	N/A	-1,203.89%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMUCD ImmunoCellular Therapeutics	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A
NXEN Nexien BioPharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMUC EOM Pharmaceuticals	N/A	N/A	N/A
IMUCD ImmunoCellular Therapeutics	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	0.09	0.09
NXEN Nexien BioPharma	N/A	0.04	0.04

Ownership

Institutional Ownership

Company	Institutional Ownership
IMUC EOM Pharmaceuticals	N/A
IMUCD ImmunoCellular Therapeutics	N/A
NSPX Inspyr Therapeutics	0.02%
NXEN Nexien BioPharma	N/A

Insider Ownership

Company	Insider Ownership
IMUC EOM Pharmaceuticals	3.28%
IMUCD ImmunoCellular Therapeutics	3.28%
NSPX Inspyr Therapeutics	0.02%
NXEN Nexien BioPharma	30.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
IMUC EOM Pharmaceuticals	3	N/A	N/A	Not Optionable
IMUCD ImmunoCellular Therapeutics	3	4.19 million	N/A	Not Optionable
NSPX Inspyr Therapeutics	1	543.15 million	N/A	Not Optionable
NXEN Nexien BioPharma	4	70.47 million	46.83 million	Not Optionable

IMUC, NXEN, IMUCD, and NSPX Headlines

Recent News About These Companies

October 31, 2023 | finance.yahoo.com

Nexien BioPharma, Inc. (NXEN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

EOM Pharmaceuticals

OTCMKTS:IMUC

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

ImmunoCellular Therapeutics

OTCMKTS:IMUCD

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.

Inspyr Therapeutics

OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Nexien BioPharma

OTCMKTS:NXEN

Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial